Development of Hybrid Cell Membrane Nanovesicles for Enhanced Pancreatic Cancer Treatment

Pancreatic cancer remains the high mortality with conventional treatments often causing side effects and chemoresistance. Therefore, advanced drug delivery systems are needed to enhance therapeutic efficacy. Recently, cell membrane-derived nanovesicles have emerged as ideal carriers offering biocompatibility, cargo protection, and tumor-targeting capabilities. Moreover, hybrid nanovesicles engineered from various cell membranes have emerged as multifunctional carriers, improving tumor targeting while reducing toxicity and overcoming chemoresistance in cancer therapy.